Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in neonatal to infantile pigs, ruminants, and other livestock that inhibits the activation of the HPG axis, growth of the gonads and inhibits gonadal production of sex hormones, which will prevent the estrous cycle until the age at slaughter. The invention comprises treatment with estrogen or estrogen in combination with androgen in the newborn to infantile females using extended drug delivery methods, with a defined duration of between 1-4 months or infantile period of growth, for the purpose of the prevention of the estrous cycle in female production animals. The drug delivery component may consist of biocompatible polymers in the form of pellets, microspheres, or gels, or in solvents or solutions (hereafter, drug complex).

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal to infantile ruminants that inhibits the activation of the HPG axis, growth of the testis and inhibits testicular production of testosterone, which prevent the development of aggressive behavior in the maturing males and the presence of male-specific odor in the meat. The invention comprises treatment with an estrogen or a combination of an estrogen and an androgen in the newborn males using extended drug delivery methods, with a defined duration of no more than 1-4 months or infantile period of growth, for the purpose of inhibiting the production of testosterone and the accumulation of male-specific odor. The drug delivery component may consist of biocompatible-/biodegradable polymers in the form of pellets, microspheres, or gels, or in solvents or solutions (hereafter, drug complex).

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: The described technology induces sterility in female animals by a single injection of progestin containing implants formulated to elevate progesterone level for an extended period to neonatal animals. The sterilant can be progesterone or its derivatives which can activate progesterone receptors. Such formulation may be achieved by using a biodegradable copolymer that releases progesterone for more than 10 days. The progesterone-containing implant can be injected intramuscularly, subcutaneously, or intraperitoneally. The progesterone released from the implants over an extended period then prevents the development of uterine glands, thereby irreversibly sterilizing the female animals.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in neonatal to infantile pigs, ruminants, and other livestock that inhibits the activation of the HPG axis, growth of the gonads and inhibits gonadal production of sex hormones, which will prevent the estrous cycle until the age at slaughter. The invention comprises treatment with estrogen or estrogen in combination with androgen in the newborn to infantile females using extended drug delivery methods, with a defined duration of between 1-4 months or infantile period of growth, for the purpose of the prevention of the estrous cycle in female production animals. The drug delivery component may consist of biocompatible polymers in the form of pellets, microspheres, or gels, or in solvents or solutions (hereafter, drug complex).

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal to infantile ruminants that inhibits the activation of the HPG axis, growth of the testis and inhibits testicular production of testosterone, which prevent the development of aggressive behavior in the maturing males and the presence of male-specific odor in the meat. The invention comprises treatment with an estrogen or a combination of an estrogen and an androgen in the newborn males using extended drug delivery methods, with a defined duration of no more than 1-4 months or infantile period of growth, for the purpose of inhibiting the production of testosterone and the accumulation of male-specific odor. The drug delivery component may consist of biocompatible-/biodegradable polymers in the form of pellets, microspheres, or gels, or in solvents or solutions (hereafter, drug complex).

Abstract: Embodiments of the present invention provide a pharmaceutical intervention in the neonatal pig that inhibits and delays development and activation of the HPG axis, growth of the boar testis and inhibits testicular production of testosterone and androstenone, which prevents the development of aggressive behavior in the maturing boars and the presence of boar taint in the meat. The invention comprises treatment with a combination of an androgen and an estrogen in the newborn male piglet using extended drug delivery methods, with a defined duration of no more than 12 weeks, for the purpose of inhibiting the production of testosterone and androstenone and the accumulation of the boar taint-inducing molecules androstenone and skatole in the fat.

Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to an animal so as to sterilize the animal.

Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to prevent and/or inhibit boar taint and/or male aggression as compared to animal that has not been administered estradiol.

Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to an animal so as to sterilize the animal. A physiologically acceptable oil or other carrier in a capsule is used to deliver the estradiol benzoate. The estradiol benzoate is delivered intraperitoneally, intramuscularly, or subcutaneously to a companion or livestock animal.

Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to an animal so as to sterilize the animal. A physiologically acceptable oil or other carrier in a capsule is used to deliver the estradiol benzoate. The estradiol benzoate is delivered intraperitoneally, intramuscularly, or subcutaneously to a companion or livestock animal.

Abstract: Methods, compositions and systems are presented to deliver estradiol benzoate to prevent and/or inhibit boar taint and/or male aggression as compared to animal that has not been administered estradiol.